Literature DB >> 21455229

Valuation of biomarkers.

Orest Hurko1, Graham K Jones.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21455229     DOI： 10.1038/nrd3417

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 3.  Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.

Authors:  Richard W Peck
Journal:  Drug Discov Today       Date:  2007-02-20       Impact factor: 7.851

4.  The uses of biomarkers in drug development.

Authors:  Orest Hurko
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 5.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373
  6 in total
  5 in total

1.  Maximizing the value of diagnostics in Alzheimer's disease drug development.

Authors:  Eric M Snyder; Jake Olin; Frank S David
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Drug development for rare mitochondrial disorders.

Authors:  Orest Hurko
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

3.  Mining biomarker information in biomedical literature.

Authors:  Erfan Younesi; Luca Toldo; Bernd Müller; Christoph M Friedrich; Natalia Novac; Alexander Scheer; Martin Hofmann-Apitius; Juliane Fluck
Journal:  BMC Med Inform Decis Mak       Date:  2012-12-18       Impact factor: 2.796

4.  Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice.

Authors:  Rana Nagarkatti; Fernanda Fortes de Araujo; Charu Gupta; Alain Debrabant
Journal:  PLoS Negl Trop Dis       Date:  2014-01-16

Review 5.  Translational precision medicine: an industry perspective.

Authors:  Dominik Hartl; Valeria de Luca; Anna Kostikova; Jason Laramie; Scott Kennedy; Enrico Ferrero; Richard Siegel; Martin Fink; Sohail Ahmed; John Millholland; Alexander Schuhmacher; Markus Hinder; Luca Piali; Adrian Roth
Journal:  J Transl Med       Date:  2021-06-05       Impact factor: 5.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.